Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.83 --0%
Revenue Growth %: +37.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: +37.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
- Lightbridge (LTBR) Misses Q3 EPS by 23c
- Fluence Energy stock falls as company replaces CEO and CFO
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
